185 related articles for article (PubMed ID: 34350622)
1. Patient-reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease.
Longoria JN; Pugh NL; Gordeuk V; Hsu LL; Treadwell M; King AA; Gibson R; Kayle M; Crego N; Glassberg J; Melvin CL; Hankins JS; Porter J
Am J Hematol; 2021 Nov; 96(11):1396-1406. PubMed ID: 34350622
[TBL] [Abstract][Full Text] [Related]
2. Neurocognitive functioning in symptomatic adults with sickle cell disease: A description and comparison with unaffected siblings.
Martin S; Roderick MC; Abel C; Wolters P; Toledo-Tamula MA; Fitzhugh C; Hsieh M; Tisdale J
Neuropsychol Rehabil; 2020 Oct; 30(9):1666-1681. PubMed ID: 30924397
[TBL] [Abstract][Full Text] [Related]
3. Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.
Smaldone A; Findley S; Bakken S; Matiz LA; Rosenthal SL; Jia H; Matos S; Manwani D; Green NS
Contemp Clin Trials; 2016 Jul; 49():134-42. PubMed ID: 27327779
[TBL] [Abstract][Full Text] [Related]
4. Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.
Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
Health Qual Life Outcomes; 2017 Jul; 15(1):136. PubMed ID: 28679417
[TBL] [Abstract][Full Text] [Related]
5. A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study.
Creary S; Chisolm D; Stanek J; Hankins J; O'Brien SH
JMIR Mhealth Uhealth; 2019 Aug; 7(8):e13452. PubMed ID: 31397291
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood.
Heitzer AM; Longoria J; Okhomina V; Wang WC; Raches D; Potter B; Jacola LM; Porter J; Schreiber JE; King AA; Kang G; Hankins JS
Br J Haematol; 2021 Oct; 195(2):256-266. PubMed ID: 34272726
[TBL] [Abstract][Full Text] [Related]
7. Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease.
Badawy SM; Thompson AA; Penedo FJ; Lai JS; Rychlik K; Liem RI
Eur J Haematol; 2017 Jun; 98(6):608-614. PubMed ID: 28306171
[TBL] [Abstract][Full Text] [Related]
8. HABIT efficacy and sustainability trial, a multi-center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol.
Smaldone A; Manwani D; Aygun B; Smith-Whitley K; Jia H; Bruzzese JM; Findley S; Massei J; Green NS
BMC Pediatr; 2019 Oct; 19(1):354. PubMed ID: 31615480
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment (HABIT) efficacy trial: Community health worker support may increase hydroxyurea adherence of youth with sickle cell disease.
Green NS; Manwani D; Aygun B; Appiah-Kubi A; Smith-Whitley K; Castillo Y; Soriano L; Jia H; Smaldone AM
Pediatr Blood Cancer; 2024 Apr; 71(4):e30878. PubMed ID: 38321562
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
[TBL] [Abstract][Full Text] [Related]
11. The association of oral hydroxyurea therapy with improved cognitive functioning in sickle cell disease.
Puffer E; Schatz J; Roberts CW
Child Neuropsychol; 2007 Mar; 13(2):142-54. PubMed ID: 17364571
[TBL] [Abstract][Full Text] [Related]
12. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease.
Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27896936
[TBL] [Abstract][Full Text] [Related]
14. Do difficulties in swallowing medication impede the use of hydroxyurea in children?
Bekele E; Thornburg CD; Brandow AM; Sharma M; Smaldone AM; Jin Z; Green NS
Pediatr Blood Cancer; 2014 Sep; 61(9):1536-9. PubMed ID: 24753149
[TBL] [Abstract][Full Text] [Related]
15. Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach.
Alberts NM; Badawy SM; Hodges J; Estepp JH; Nwosu C; Khan H; Smeltzer MP; Homayouni R; Norell S; Klesges L; Porter JS; Hankins JS
JMIR Mhealth Uhealth; 2020 May; 8(5):e14884. PubMed ID: 32383683
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of mDOT-HuA study: a randomized trial to assess the effect of mobile-directly observed therapy on adherence to hydroxyurea in adults with sickle cell anemia in Tanzania.
Makubi A; Sasi P; Ngaeje M; Novelli EM; Mmbando BP; Gladwin MT; Makani J
BMC Med Res Methodol; 2016 Oct; 16(1):140. PubMed ID: 27756209
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Instrumental Activities of Daily Living in Older Adults with Subjective Cognitive Decline Using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT).
Atkins AS; Khan A; Ulshen D; Vaughan A; Balentin D; Dickerson H; Liharska LE; Plassman B; Welsh-Bohmer K; Keefe RSE
J Prev Alzheimers Dis; 2018; 5(4):216-234. PubMed ID: 30298179
[TBL] [Abstract][Full Text] [Related]
18. Neurocognitive functioning in preschool children with sickle cell disease.
Heitzer AM; Cohen DL; Okhomina VI; Trpchevska A; Potter B; Longoria J; Porter JS; Estepp JH; King A; Henley M; Kang G; Hankins JS
Pediatr Blood Cancer; 2022 Mar; 69(3):e29531. PubMed ID: 34971013
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Nevitt SJ; Jones AP; Howard J
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
